Clinical trials: Dementia, Alzheimer's Type
Alzheimer Disease
Long Term Extension Study Evaluating Safety, Tolerability and Immunogenicity Of ACC-001 In Subjects With Mild To Moderate Alzheimer's Disease
The purpose of this study is to assess the long term safety, tolerability, and immunogenicity of ACC-001, an investigational active immunization product+, in subjects with mild to moderate Alzheimer's disease.
- Trial name
- NCT00955409
- Testing
- ACC-001(3µg) + QS21, ACC-001(10µg) + QS21, ACC-001(30µg) + QS21
- Where
- 17 sites in France, Germany and 1 more
- Volunteers
- 160 people
- Sponsor
- Pfizer
Alzheimers Disease
A Study to Evaluate the Efficacy and Safety of Gantenerumab in Participants at Risk for or at the Earliest Stages of Alzheimer's Disease (AD)
A study to evaluate the efficacy and safety of gantenerumab in amyloid-positive, cognitively unimpaired participants at risk for or at the earliest stages of AD.
- Trial name
- SKYLINE (NCT05256134)
- Testing
- Gantenerumab
- Where
- 63 sites in United States, Argentina and 8 more
- Volunteers
- 25 people
- Sponsor
- Hoffmann-La Roche
Alzheimer Disease, Mild Cognitive Impairment
Early Diagnosis of Alzheimer-like Dementia: Benefit of MRI and PET Imaging
The physio-pathology of Alzheimer's disease (AD) remains unknown and there is no cure. Thus, the search for objective markers of preclinical first signs of cognitive impairment, is currently a major public health issue.
- Conditions
- Alzheimer Disease, Mild Cognitive Impairment, Vascular Dementia
- Trial name
- NCT01815112
- Testing
- Magnetic resonance imaging, Positron emission tomography
- Where
- 2 sites in France
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Alzheimer Disease, Agitation,Psychomotor
Clinical Trial on Agitation in Alzheimer's Dementia
The purpose of this study is to assess the efficacy of the oral medication IGC-AD1, a THC-based (Delta-9-Tetrahydrocannabinol) formulation administered twice a day on Agitation in patients with mild to severe dementia from…
- Conditions
- Alzheimer Disease, Agitation,Psychomotor, Care Giving Burden, NPS
- Trial name
- CALMA (NCT05543681)
- Testing
- IGC-AD1-Active
- Where
- 28 sites in United States, Canada and 1 more
- Volunteers
- 164 people
- Sponsor
- IGC Pharma, LLC
Mild to Severe Alzheimer's Disease
The Effectiveness And Safety Of Donepezil Hydrochloride (E2020) In Subjects With Mild To Severe Alzheimer's Disease Residing In An Assisted Living Facility
This is a study to determine the effectiveness and safety of donepezil hydrochloride (E2020) used to treat residents of assisted living facilities diagnosed with mild, moderate, or severe stage Alzheimer's disease.
- Trial name
- NCT00571064
- Testing
- Donepezil HCl
- Where
- 36 sites in United States
- Volunteers
- 97 people
- Sponsor
- Eisai Inc.
Dementia, Alzheimer Disease
Making Connections Thru Music
Healthcare systems around the world, including within the United States, have long-established shortages of trained caregivers. The American Health Care Association states that "the health care system has experienced a shortage…
- Conditions
- Dementia, Alzheimer Disease, Vascular Dementia
- Trial name
- MCTM (NCT06079216)
- Testing
- Volunteer Led Making Connections Thru Music, Staff Led Making Connections Thru Music
- Where
- 2 sites in United States
- Volunteers
- 196 people, healthy volunteers welcome
- Sponsor
- Hopeful Aging
Alzheimer's Disease
Study of Octohydroaminoacridine Succinate Tablets in Patients With Alzheimer's Disease
The main purpose of this study is to evaluate the safety and efficacy of Octohydroaminoacridine Succinate tablets and find the optimal dose in patients with mild to moderate Alzheimer's Disease.
- Trial name
- NCT01569516
- Testing
- Octohydroaminoacridine Succinate Tablets
- Where
- 13 sites in China
- Volunteers
- 288 people
- Sponsor
- Changchun Huayang High-tech Co., Ltd
Schizophrenia, Alzheimer's Disease
Side Effects of Newer Antipsychotics in Older Adults
This study will compare four atypical antipsychotic medications in terms of the risk of specific side effects each of them presents in middle-aged and elderly individuals.
- Conditions
- Schizophrenia, Alzheimer's Disease, Dementia
- Trial name
- NCT00245206
- Testing
- Aripiprazole, Olanzapine, Risperidone
- Where
- United States
- Volunteers
- 406 people, healthy volunteers welcome
- Sponsor
- Veterans Medical Research Foundation
Severe Alzheimer's Disease
Evaluating The Impact Of Donepezil Hydrochloride (Aricept) On Behavioral And Psychological Symptoms In Patients With Severe Alzheimer's Disease
A 12-week, multicenter, randomized, double-blind, placebo-controlled phase IV study. Approximately 200 subjects will be enrolled, half will receive active drug (donepezil hydrochloride) and half will receive matching placebo at…
- Trial name
- NCT00711204
- Testing
- Donepezil Hydrochloride (Aricept)
- Where
- United States
- Sponsor
- Eisai Inc.
MCI-AD, Early Stage Alzheimer's Disease, MCI-DLB, Early Stage Dementia With Lewy Bodies
A Diagnostic Test for Dementia With Lewy Bodies
The Syn-D Study will be evaluating α-synuclein in patients with suspected MCI-AD and MCI-DLB. Using a simple diagnostic test will improve clinical accuracy in diagnosing, earlier diagnosis, and distinguish between…
- Trial name
- NCT05479552
- Testing
- Syn-One Test
- Where
- 12 sites in United States
- Volunteers
- 80 people
- Sponsor
- CND Life Sciences
Alzheimer Disease
Lecanemab for Early Onset Familial Alzheimer's Disease
The goal of this observational study is to learn about the efficacy of Lecanemab treatment for early-onset familial Alzheimer's disease (AD) in patients under 65 years of age with a family history of AD.
- Trial name
- NCT06883019
- Where
- 15 sites in China
- Volunteers
- 114 people
- Sponsor
- RenJi Hospital
Alzheimer's Disease
A Phase III Multi Regional Clinical Trial (MRCT) of Tricaprilin in Mild to Moderately Severe Probable Alzheimer's Disease With Optional Open Label Extension
This is Phase 3 study, multi-centre, double-blind, placebo controlled, parallel group to evaluate the effects of AC-SD-03 on the efficacy and safety among participants with mild to moderate Alzheimer's Disease.
- Trial name
- NCT04187547
- Testing
- Tricaprilin
- Sponsor
- Cerecin
Depression, Anxiety
Effectiveness of the Safe Haven Application (App) Among Undergraduates
The goal of this randomized controlled trial is to evaluate the effectiveness of the Safe Haven app in reducing mental health symptoms and enhancing mental health literacy in undergraduates at a national university in southern…
- Trial name
- NCT07340983
- Testing
- Safe Haven App
- Where
- Taiwan
- Volunteers
- 68 people, healthy volunteers welcome
- Sponsor
- National Cheng-Kung University Hospital
Alzheimer's Disease
Safety and Efficacy of Donepezil HCl 23 mg in Patients With Moderate to Severe Alzheimer's Disease
This is a multi-center, open-label, single-arm, prospective, phase IV trial, evaluating safety and efficacy of donepezil hydrochloride in patients with moderate to severe Alzheimer's disease.
- Trial name
- SAVE (NCT02097056)
- Testing
- Donepezil HCL
- Where
- 13 sites in South Korea
- Volunteers
- 171 people
- Sponsor
- Eisai Korea Inc.
Alzheimers Disease
An Observational Study of Aducanumab-avwa in Participants With Alzheimer's Disease in the US
This is a prospective, single-arm, multicenter, non-interventional study of aducanumab-avwa as prescribed in the post-marketing setting in the US.
- Trial name
- NCT05097131
- Where
- 22 sites in United States
- Volunteers
- 29 people
- Sponsor
- Biogen
Subjective Cognitive Concerns, Mild Cognitive Impairment
Digital Accessible Remote Olfactory Mediated Health Assessments for Preclinical AD
The goal of this study is to objectively test one's sense of smell, called olfaction, in participants with Subjective Cognitive Concerns (SCC), Mild Cognitive Impairment, Mild Behavioral Impairment (MBI), and age-matched…
- Conditions
- Subjective Cognitive Concerns, Mild Cognitive Impairment, Mild Behavioral Impairment, Healthy Aging
- Trial name
- NCT05881239
- Testing
- AROMHA Brain Health Test
- Where
- United States
- Volunteers
- 250 people, healthy volunteers welcome
- Sponsor
- Massachusetts General Hospital
Alzheimer's Disease
Efficacy and Safety of Filgrastim in Alzheimer's Disease
Filgrastim (G-CSF) is widely used for treatment of patients who have a deficiency of white blood cells. It is also routinely used to stimulate and mobilize stem/progenitor cells for bone marrow transplantation.
- Trial name
- FFAD (NCT01617577)
- Testing
- G-CSF; filgrastim
- Where
- United States
- Volunteers
- 8 people
- Sponsor
- University of South Florida
Alzheimer's Disease, Mild Cognitive Impairment
Dopaminergic Enhancement of Learning and Memory in Healthy Adults and Patients With Dementia/Mild Cognitive Impairment
This study aims to determine whether levodopa is effective in boosting learning and memory in healthy subjects and patients with dementia or Mild Cognitive Impairment.
- Conditions
- Alzheimer's Disease, Mild Cognitive Impairment, Healthy
- Trial name
- NCT00306124
- Testing
- Levodopa
- Where
- Germany
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital Muenster
Alzheimer Disease
Perturbation Training Reduces Falls in People With Alzheimer's Disease (AD)
This study will examine the overall capacity of people with Alzheimer's disease learning fall-resistant skills from perturbation training.
- Trial name
- STAD (NCT05205980)
- Testing
- Perturbation training
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Georgia State University
Alzheimer's Disease (AD)
Trial of Oxaloacetate in Alzheimer's Disease (TOAD)
The purpose of this study is to determine if oxaloacetate (OAA) is safe and tolerable at doses of up to 2 grams per day in people with Alzheimer's disease (AD).
- Trial name
- TOAD (NCT02593318)
- Testing
- Oxaloacetate (OAA) 1g, Oxaloacetate (OAA) 2g
- Where
- United States
- Volunteers
- 32 people
- Sponsor
- Russell Swerdlow